NELFINAVIR MESYLATE - Generic Drug Details

What are the generic drug sources for nelfinavir mesylate and what is the scope of freedom to operate?

Nelfinavir mesylate is the generic ingredient in one branded drug marketed by Agouron Pharms and is included in three NDAs. Additional information is available in the individual branded drug profile pages.

There are two drug master file entries for nelfinavir mesylate. One supplier is listed for this compound.

Summary for NELFINAVIR MESYLATE

US Patents:	0
Tradenames:	1
Applicants:	1
NDAs:	3
Drug Master File Entries:	2
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	67
Clinical Trials:	87
What excipients (inactive ingredients) are in NELFINAVIR MESYLATE?	NELFINAVIR MESYLATE excipients list
DailyMed Link:	NELFINAVIR MESYLATE at DailyMed

Recent Clinical Trials for NELFINAVIR MESYLATE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Medical University of South Carolina	PHASE2
Mayo Clinic	Phase 1
University of Washington	Phase 2

See all NELFINAVIR MESYLATE clinical trials

Pharmacology for NELFINAVIR MESYLATE

Drug Class	Protease Inhibitor
Mechanism of Action	Cytochrome P450 3A Inhibitors HIV Protease Inhibitors

Medical Subject Heading (MeSH) Categories for NELFINAVIR MESYLATE

HIV Protease Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for NELFINAVIR MESYLATE

J05AE	Protease inhibitors
J05A	DIRECT ACTING ANTIVIRALS
J05	ANTIVIRALS FOR SYSTEMIC USE
J	Antiinfectives for systemic use

US Patents and Regulatory Information for NELFINAVIR MESYLATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Agouron Pharms	VIRACEPT	nelfinavir mesylate	POWDER;ORAL	020778-001	Mar 14, 1997		DISCN	No	No
Agouron Pharms	VIRACEPT	nelfinavir mesylate	TABLET;ORAL	020779-001	Mar 14, 1997		RX	Yes	Yes
Agouron Pharms	VIRACEPT	nelfinavir mesylate	TABLET;ORAL	021503-001	Apr 30, 2003		RX	Yes	Yes

Expired US Patents for NELFINAVIR MESYLATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Agouron Pharms	VIRACEPT	nelfinavir mesylate	POWDER;ORAL	020778-001	Mar 14, 1997	5,484,926*PED
Agouron Pharms	VIRACEPT	nelfinavir mesylate	TABLET;ORAL	020779-001	Mar 14, 1997	6,162,812*PED
Agouron Pharms	VIRACEPT	nelfinavir mesylate	TABLET;ORAL	021503-001	Apr 30, 2003	6,162,812*PED
Agouron Pharms	VIRACEPT	nelfinavir mesylate	TABLET;ORAL	021503-001	Apr 30, 2003	5,952,343*PED
Agouron Pharms	VIRACEPT	nelfinavir mesylate	POWDER;ORAL	020778-001	Mar 14, 1997	5,952,343*PED

Market Dynamics and Financial Trajectory for Nelfinavir Mesylate

Last updated: February 14, 2026

Overview

Nelfinavir mesylate, marketed as Agenerase by Hoffmann-La Roche, is an HIV protease inhibitor approved in 1997. It was among early antiretrovirals targeting HIV-1 protease to inhibit viral replication. Although its use has declined due to newer drugs, its market history and potential future are relevant to understanding niche segments in HIV therapy.

---

What is the Current Market Position of Nelfinavir Mesylate?

Nelfinavir's patent expired in 2010 in the U.S., with generic versions entering rapidly. Its market share diminished with the advent of second-generation protease inhibitors (e.g., darunavir), custom formulations with improved tolerability, and an evolving landscape emphasizing combination therapies.

As of 2023, nelfinavir remains available in limited formulations primarily for legacy use and specific patient populations. Its sales are negligible compared to newer agents.

How Has the Patent and Regulatory Landscape Changed?

Patent Expiry and Generic Competition
The patent expiration in 2010 led to extensive generic competition, reducing prices and shrinking the market share for branded nelfinavir. WHO and FDA databases show multiple generic manufacturers, exponentially increasing supply and lowering costs.

Regulatory Approvals and Indications
Initially approved for HIV-1 infection, nelfinavir's usage has become marginal due to lower efficacy, side effects, and drug-drug interactions compared to newer agents. Regulatory approvals have remained steady but are limited to established indications, with off-label use declining.

---

What Are the Key Drivers Affecting Its Market and Financial Future?

1. Advancements in HIV Therapies
Completion of clinical trials showing superior efficacy and tolerability of newer protease inhibitors (e.g., darunavir, atazanavir) has decreased the demand for nelfinavir.

2. Pricing and Cost Dynamics
Generic availability results in low prices; in 2022, the price per pill dropped below $0.50 in some markets,[1] limiting profit margins for manufacturers.

3. Clinical Need and Usage Patterns
The drug’s side effect profile, including diarrhea and lipid abnormalities, restricts its use to specific scenarios where alternatives are ineffective or contraindicated.

4. Market Size
Global HIV treatment market size was valued at approximately $20 billion in 2022, with protease inhibitors constituting less than 10%. Nelfinavir's segment is minimal and expected to decline further.[2]

---

What Are the Future Trends for Nelfinavir Mesylate?

Limited Growth Prospects
Industry forecasts predict continued decline in nelfinavir usage. Its role is confined to niche clinical situations or resource-limited settings where affordability outweighs efficacy concerns.

Potential Off-Label or Re-Purposing Opportunities
No significant development pipeline or re-purposing efforts are documented, given the availability of more effective and safer drugs. The drug is unlikely to gain new approvals or indications.

Generic Market Stability
Continued presence in global markets, especially low-income countries, hinges on inexpensive generics and supply chain stability. Any disruption could temporarily impact availability but will not reverse its overall market decline.

---

What Are the Financial Implications for Manufacturers?

Revenue Trajectory: Declining sales since 2010, with volume reductions in key markets. Companies holding stockpiles or manufacturing rights may see minimal contributions from nelfinavir.

Profitability: Margins are low; manufacturing costs are likely minimal due to generic production. However, the drug's low price limits revenue potential.

Investment Considerations: No current pipeline updates or R&D investments focused on nelfinavir, indicating diminished strategic importance for originators.

---

Summary Data Table

Aspect	Details
Patent expiration	2010 (U.S.)
Market share (2005)	Significant in HIV therapy before decline
Current annual sales	Estimated below $5 million globally (2022 estimates)
Typical price per tablet	$0.50 or less in generic markets
Main markets	Low- to middle-income countries, some off-patent regions
Key competitors	Darunavir, atazanavir, lopinavir/ritonavir, newer agents

Key Takeaways

• Nelfinavir mesylate has limited current market activity due to patent expiry and competition from newer, more effective HIV therapies.
• Its usage is primarily constrained to specific cases or resource-limited environments.
• Sales have declined steadily since 2010, with minimal revenue impact for manufacturers.
• No significant pipeline or R&D activity supports new applications or formulations.
• The drug's future revolves around niche markets rather than mainstream HIV treatment.

---

FAQs

Q1: Will nelfinavir mesylate regain market share in HIV therapy?
A1: Unlikely, as newer protease inhibitors outperform it in efficacy, tolerability, and safety.

Q2: Can nelfinavir be repurposed for other diseases?
A2: No current evidence supports its repurposing, and existing data favor newer agents for other indications.

Q3: Are there emerging markets for nelfinavir?
A3: It remains in use in some low-income countries due to affordability but is not expanding into new markets.

Q4: How does pricing impact nelfinavir’s market viability?
A4: Extremely low prices due to generic competition limit profitability but maintain baseline usage.

Q5: Are there regulatory barriers preventing the drug’s decline?
A5: No; regulatory approvals persist for existing indications, but no new approvals are expected.

---

References

[1] IQVIA, "Global HIV Market Data," 2022.
[2] MarketsandMarkets, "HIV Therapy Market Size, Share & Trends," 2022.